Your session is about to expire
What is Lynparza
Approved as Treatment by the FDA
Olaparib, commonly known as Lynparza, is approved by the FDA for 8 uses like Advanced Epithelial Ovarian Cancer and Advanced Primary Peritoneal Carcinoma .Effectiveness
When to interrupt dosage
The measure of Lynparza is contingent upon the diagnosed affliction, for example, Pharmacotherapy, Malignant Peritoneal Neoplasm and Ovarian Cancer. The dose fluctuates as per the method of delivery (e.g. Tablet - Oral or Oral) stated in the table below.Warnings
There are 20 known major drug interactions with Lynparza.Lynparza Novel Uses: Which Conditions Have a Clinical Trial Featuring Lynparza?
At present, 211 active studies are analyzing the potential of Lynparza to address Ovarian Cancer, Hallucinations, Somatic and Metastatic Breast Cancer.Lynparza Reviews: What are patients saying about Lynparza?
Patient Q&A Section about lynparza
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Lynparza a chemotherapy?
"A targeted therapy is a cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread.
Lynparza is the trade name for olaparib, a chemotherapy drug. In some cases, health care professionals may use the generic name olaparib when referring to the trade drug name Lynparza. Lynparza is a targeted therapy, meaning it targets changes in cancer cells that help them grow, divide, and spread."
What cancers does Lynparza treat?
"LYNPARZA is used to treat adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have a certain type of mutated (inherited or acquired) BRCA gene."
Does Lynparza cure cancer?
"While the approval of Lynparza is great news for treating cancers in BRCA mutation carriers, much work remains. Lynparza has been approved for use in ovarian cancer patients who received three prior chemotherapies, making it a “fourth line” drug."
How long do you stay on Lynparza?
"On average, patients taking Lynparza stayed on the medication for 24.6 months, while those taking placebo only stayed on the medication for 13.9 months."